Tiotropium
- Generic Name
- Tiotropium
- Brand Names
- Inspiolto Respimat, Spiriva, Spiriva Respimat, Stiolto
- Drug Type
- Small Molecule
- Chemical Formula
- C19H22NO4S2
- CAS Number
- 186691-13-4
- Unique Ingredient Identifier
- 0EB439235F
- Background
Tiotropium is a long-acting, antimuscarinic bronchodilator used in the management of chronic obstructive pulmonary disease (COPD) and asthma. Tiotropium acts mainly on M3 muscarinic receptors located in the airways to produce smooth muscle relaxation and bronchodilation.
...
- Indication
Tiotropium powder for inhalation is indicated for the maintenance of bronchospasm in COPD and to prevent exacerbations of COPD. A combination tiotropium and olodaterol metered inhalation spray is indicated for maintenance of COPD. A tiotropium inhalation spray is indicated for the maintenance of bronchospasm in COPD, to prevent exacerbations of COPD, and to ...
- Associated Conditions
- Asthma, Bronchitis, Bronchoconstriction, Chronic Bronchitis, Chronic Obstructive Pulmonary Disease (COPD), Emphysema, Exacerbation of COPD
- Associated Therapies
- -
A Collection of Vital Status and Pulmonary Medication Usage Data for Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Withdrew Prematurely From Tiotropium Inhalation Solution Delivered by the Respimat Inhaler
- First Posted Date
- 2014-06-24
- Last Posted Date
- 2014-11-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 441
- Registration Number
- NCT02172560
- Locations
- 🇦🇺
Boehringer Ingelheim Investigational Site 61503, Nedlands, Western Australia, Australia
🇦🇺Boehringer Ingelheim Investigational Site 61405, Perth, Western Australia, Australia
🇦🇺Boehringer Ingelheim Investigational Site 61502, Adelaide, South Australia, Australia
Lung Function and Patient Preference With QVA149 vs. Tiotropium in COPD Patients
- Conditions
- Interventions
- First Posted Date
- 2014-04-29
- Last Posted Date
- 2017-04-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 88
- Registration Number
- NCT02125734
- Locations
- 🇩🇪
Novartis Investigative Site, Warendorf, Germany
To Evaluate the Effect of Inhaled Medication Together With Exercise and Activity Training on Exercise Capacity and Daily Activities in Patients With Chronic Lung Disease With Obstruction of Airways
- Conditions
- Interventions
- First Posted Date
- 2014-03-12
- Last Posted Date
- 2017-01-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 304
- Registration Number
- NCT02085161
- Locations
- 🇬🇧
Boehringer Ingelheim Investigational Site, Sheffield, United Kingdom
Evaluation of Long-Acting Muscarinic Antagonists in COPD
- Conditions
- Interventions
- First Posted Date
- 2014-01-17
- Last Posted Date
- 2019-04-12
- Lead Sponsor
- University of Dundee
- Target Recruit Count
- 15
- Registration Number
- NCT02039050
- Locations
- 🇬🇧
Asthma and Allergy Research Group, University of Dundee, Dundee, United Kingdom
Study to Evaluate the Effect on Lung Function and ECG When a Combination of Tiotropium Plus Olodaterol is Administered to Patients With COPD Either From a Single Inhaler or Each Compound is Administered After Each Other From Two Different Inhalers
- Conditions
- Interventions
- First Posted Date
- 2014-01-08
- Last Posted Date
- 2015-07-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 53
- Registration Number
- NCT02030535
- Locations
- 🇩🇪
1237.7.49004 Boehringer Ingelheim Investigational Site, Berlin, Germany
🇩🇪1237.7.49007 Boehringer Ingelheim Investigational Site, Frankfurt, Germany
🇩🇪1237.7.49005 Boehringer Ingelheim Investigational Site, Berlin, Germany
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
- Conditions
- Interventions
- First Posted Date
- 2013-12-10
- Last Posted Date
- 2016-01-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 809
- Registration Number
- NCT02006732
- Locations
- 🇺🇸
1237.26.10613 Boehringer Ingelheim Investigational Site, St. Louis, Missouri, United States
🇺🇸1237.26.10606 Boehringer Ingelheim Investigational Site, Medford, Oregon, United States
🇦🇺1237.26.61004 Boehringer Ingelheim Investigational Site, Concord, New South Wales, Australia
Characterization of Lung Function Profile of Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared to Fluticasone Propionate + Salmeterol Fixed Dose Combination in COPD Patients
- Conditions
- Interventions
- First Posted Date
- 2013-10-25
- Last Posted Date
- 2016-02-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 229
- Registration Number
- NCT01969721
- Locations
- 🇨🇿
1237.11.42004 Boehringer Ingelheim Investigational Site, Rokycany, Czech Republic
🇩🇪1237.11.49003 Boehringer Ingelheim Investigational Site, Großhansdorf, Germany
🇩🇪1237.11.49005 Boehringer Ingelheim Investigational Site, Hamburg, Germany
Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)
- Conditions
- Interventions
- First Posted Date
- 2013-10-17
- Last Posted Date
- 2015-11-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 813
- Registration Number
- NCT01964352
- Locations
- 🇺🇸
1237.25.10508 Boehringer Ingelheim Investigational Site, Spartanburg, South Carolina, United States
🇧🇪1237.25.32002 Boehringer Ingelheim Investigational Site, Turnhout, Belgium
🇧🇪1237.25.32004 Boehringer Ingelheim Investigational Site, Brussels, Belgium
Effect of Glycopyrronium on Morning Symptoms and Pulmonary Function in Patients With Moderate to Severe COPD
- Conditions
- Interventions
- First Posted Date
- 2013-10-10
- Last Posted Date
- 2016-04-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 124
- Registration Number
- NCT01959516
- Locations
- 🇬🇧
Novartis Investigative Site, Wishaw, United Kingdom
Efficacy of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Interventions
- First Posted Date
- 2013-08-14
- Last Posted Date
- 2015-01-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 152
- Registration Number
- NCT01922271
- Locations
- 🇩🇪
Novartis Investigative Site, Sonneberg, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.